Liver cancer tissue specific RNA (Ribose Nucleic Acid) interference system, as well as construction method and application method thereof

Abstract

The invention provides a liver cancer tissue specific RNA (Ribose Nucleic Acid) interference system, as well as a construction method and an application method thereof. The liver cancer tissue specific RNA interference system comprises an AFP (Alpha Fetal Protein)-Cre vector and an LoxP-shRNA vector which are both constructed by lentiviral vectors, wherein the AFP-Cre vector contains an AFP promoter and a Cre recombinase gene placed at the downstream of the AFP promoter; the LoxP-shRNA vector contains a reconstructive H6 promoter and an shRNA sequence placed at the downstream of the U6 promoter; the reconstructive U6 promoter contained in the LoxP-shRNA vector is the U6 promoter in which a structure, capable of indicating whether the AFP-Cre / LoxP-shRNA system is in work, is inserted inside; and the structure, capable for indicating whether the AFP-Cre / LoxP-shRNA system is in work, is shown as LoxP-CMV-eGFP-LoxP. The RNA interference system, provided by the invention, has the characteristics of being high in liver cancer tissue specificity, long-lasting in effect, high in efficiency, excellent in indication performance, and simple and convenient in operation; and the liver cancer tissue specific RNA interference system enables the liver cancer RNA interferential targeted treatment of liver cancer, provides high convenience to relative research and analysis, and can be widely applied to the treatment of the liver cancer and the basic research.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a liver cancer tissue-specific RNA interference system and its establishment and application method. Background technique [0002] Primary liver cancer is a malignant disease that seriously threatens human health. Although its morbidity rate only ranks sixth in the incidence rate of malignant tumors, its mortality rate ranks third. China is a country with a high incidence of primary liver cancer, accounting for about 55% of the global incidence. The third national death cause retrospective sampling survey report shows that liver cancer is the second cause of death related to malignant tumors in my country (in cities and men it is the first cause of death). Liver cancer is often diagnosed at an advanced stage, and its treatment methods are limited. How to effectively treat liver cancer is a major problem that needs to be solved urgently in our country. [0003] In recent year...

AI Technical Summary

Problems solved by technology

In addition, siRNA or type III promoter-driven shRNA has a short duration of action (rarely more than a week or several weeks, while cancer therapy must be able to maintain at least longer); at the same time, the transfection efficiency of both is low, and the uptake by cells limited, these are important challenges for current therapeutic applications of RNAi

Images